Restructuring Plans

6 Months Ended

Jun. 30, 2025

Restructuring and Related Activities [Abstract]

AbbVie continuously evaluates its operations to identify opportunities to optimize its manufacturing and R&D operations, commercial infrastructure and administrative costs and to respond to changes in its business environment. As a result, AbbVie management periodically approves individual restructuring plans to achieve these objectives. As of June 30, 2025 and 2024, no such plans were individually significant. Restructuring charges were $136 million for the three months and $153 million for the six months ended June 30, 2025 and $49 million for the three months and $64 million for the six months ended June 30, 2024. These charges are recognized in cost of products sold, R&D expense and SG&A expense in the condensed consolidated statements of earnings based on the classification of the affected employees or the related operations.

The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2025:


(in millions)
Accrued balance as of December 31, 2024	$	236
Restructuring charges	46
Payments and other adjustments	(41)
Accrued balance as of June 30, 2025	$	241

AbbVie Inc. 10-Q